Intelisci’s Post

🔦 Speaker Spotlight 🔦 Join Kinkini Roy, PhD and 80+ LNP experts to discuss critical strategies to develop stable, safe and site specific LNP drug products at the 3rd Lipid Nanoparticles Development Europe Summit (24-26 September, Berlin).   Take a look at the agenda: https://ter.li/1dmn5   We caught up with Kinkini recently, who told us how excited they are to be presenting their work alongside Sandipan Dawn, PhD in an exclusive deep-dive workshop titled ”Exploring the Rise of LNP Alternative Drug Delivery Systems”. In this hands-on session, they will compare the challenges faced with LNPs alongside polymeric systems, pinpointing translatable learnings to take forward.   See full details of their session: https://ter.li/1dmn5s   Unite with these industry leaders at the ultimate end-to-end LNP development discussion, to accelerate the clinical development of lipid nanoparticles and advance the therapeutic potential for mRNA, siRNA, CRISPR, cell therapy and lots more.   #LipidNanoparticles #DrugDevelopment #LNP #Therapeutics #mRNA #siRNA #CRISPR #CellTherapy #Pharma #Biotech #Innovation

Alzheimer’s disease presents a major unmet medical need with an estimated 1 in 9 people aged 65+ affected. InMed's INM-901 is a novel drug candidate that has demonstrated that it may address multiple pathologies related to #Alzheimers disease progression. In this video, InMed's CEO Eric A. Adams goes over the INM-901 program and details of the preclinical studies as well as #Alzheimer's pathology: https://ow.ly/ccol50SKyXV $INM #pharma #biotech #AlzheimersStudies

We’re pleased to announce our partnership with Biopredic International for the production of pooled suspension human hepatocytes.   Despite their crucial role in assessing drug metabolism and hepatic clearance, current hepatocyte cell models have a limited lifespan which hinders long-term studies. This agreement combines Biopredic’s know-how in cell pooling with our expertise and production capacity in sourcing primary hepatocytes to provide DMPK researchers with access to large batches of pooled suspension human hepatocyte cell models. The pooled hepatocytes have an increased lifespan of over 12 hours, increasing throughput capacities and reducing assay costs.   Learn more about the hepatocytes and read the full press release here: https://rb.gy/wuyfw8   #Hepatocytes #CellModels #DPMK #DrugDiscovery #Liver

Alliance for Regenerative Medicine (ARM) and NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals co-sponsored a Scientific Exchange with CGT developers, FDA staff, and industry stakeholders - including Cellistic founder & CTO Stefan Braam. They discussed reusable technology elements to boost CGT development efficiency and availability. Emphasis was placed on FDA-designated Platform Technologies to accelerate product development and the need for broader access to these technologies 💡📝Explore the whitepaper summary and access the full publication on our blog. #Cellistic #CellTherapy #iPSCs #FDA #ARM #NIIMBL #whitepaper

The Rise of Peptides in 2024 Unleashing the Potential of Peptide Therapeutics with AI Innovations As we steer towards 2024, an unprecedented surge is observed in the peptide therapeutics market, a progression fueled by innovative AI technologies. Cutting-edge advancements like genetic code expansion and PEGylation are not just buzzwords but catalysts transforming the potency and availability of peptide treatments. Dive deep into the meticulous research published in Nature to unravel the promising horizon awaiting these therapies. Witness firsthand how AI is not just a participant but a game-changer, pioneering the creation of new peptides and enhancing processes like PEGylation to refine drug attributes. Learn more about the exciting advancements in peptide therapeutics and AI’s role in this field. Explore our Newsletter https://lnkd.in/eau6sC6a. Must Reads: - Unraveling The Peptide Therapeutics Market - A 2030 Outlook https://lnkd.in/eq_29ZPY - AI’s Role in Accelerated Peptide Discovery - A Nature Study https://lnkd.in/eAp8MEXF - Technology Breakthroughs Shaping Peptide Discovery - Nature’s Insight https://lnkd.in/ekmNt7XP - Peptilogics and Cerebras Systems Partner on AI Solutions - HPCwire https://lnkd.in/ec3frA2b #PeptideRevolution #AIInHealthcare #FutureOfMedicine #BioTechInnovation

#LipidNanoparticles, #RNATherapeutics, #QualityAssessment | 𝗛𝗼𝘄 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗶𝘀 𝘁𝗵𝗲 𝗿𝗼𝗹𝗲 𝗼𝗳 𝗿𝗼𝗯𝘂𝘀𝘁 𝗮𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝘁𝗵𝗼𝗱𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀? 🟣 𝗔𝗶𝗺 To assess the quality of lipid nanoparticles (LNPs) used for in-vivo intracellular delivery of nucleic acids through comprehensive analytical methods. 🟣 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀 Evaluation and comparison of analytical protocols for chemical composition, drug loading, particle size, concentration, and stability. Assessment of measurement protocols for reproducibility, robustness, and correlative approaches. 🟣 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲 This research highlights the importance of detailed characterization strategies to support the quality assessment of RNA therapeutics. Check here for more: https://lnkd.in/ectX4Dic Thank you, Jérémie Parot, Dora Mehn, Hanna Jankevics Jones, Natalia Markova, Michele Carboni, Camilla Olaisen, Andrea Draget Hoel, Margret Asa Sigfusdottir, Florian Meier, Roland Drexel, Gabriele Vella, Birgitte Hjelmeland McDonagh, Hansen Terkel, Thanh-Huong Bui, Geir Klinkenberg, Torkild Visnes, sabrina gioria, Patricia Urban Lopez, Adriele Prina Mello, Sven Even F. Borgos, Luigi Calzolai.

#transcript Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid system, their lead drug candidate targets the major organs where CB1 receptors reside in fat tissue to increase mitochondrial activity and burn more fat.  #SkyeBioscience #Obesity #EndocannabinoidSystem #WeightLossDrug #CB1Receptor #GLP1 skyebioscience.com https://lnkd.in/gp3g2cZ3

One of Silo’s two preclinical programs is SPU-16, a CNS-homing peptide targeting #multiplesclerosis (MS), the most widespread disabling #neurological condition of young adults. Our research and development are being conducted through collaboration with the University of Maryland, Baltimore (UMB). More details on SPU-16 here: https://bit.ly/40vPhAN #Science #Biotech #Biotechnology #Biopharma #MultipleSclerosis

Alzstatin® – with a focus on Alzheimer’s disease Our disease-modifying research platform Alzstatin consists of gamma-secretase modulators (GSMs). GSMs reduces the production of toxic amyloid beta (Aβ42) in the brain. Aβ42 plays a key pathogenic role in Alzheimer’s disease and begins to accumulate in the brain years before clear symptoms start to develop. Innovative small molecule disease-modifying and preventive drugs for Alzheimer’s disease are under development within the Alzstatin platform. They are intended to enable simple administration of the drug and be more cost-effective. The two Alzstatin projects are in the preclinical development phase. https://lnkd.in/dt-nNHS #alzstatin #Aβ42 #GSMs #peptides #Alzheimers #alzecure #Alzheimerfonden #costeffective

How can radiomic analysis optimise drug development trajectories? Radiomic analysis allows for the quantification of the magnitude of effect of therapeutics, analysing total tumour burden to get a better understanding of patient response.    Lesion specific analysis quantifies feature changes such as shape, texture and intensity from medical images across multiple timepoints to assess treatment response at the individual lesion level.   At Radiomics.bio we offer objective measurements comparing response differences of lesions in multiple organs, detecting signs of lesion specific response to optimise drug development trajectories.